Nanomega CryoAI is advancing structure-based drug discovery by combining cutting-edge cryo-electron microscopy (cryo-EM) with artificial intelligence. Using proprietary algorithms and advanced imaging technologies, the company’s end-to-end AI-powered platform accelerates therapeutic discovery by enabling rapid target identification, improved modeling accuracy, and breakthroughs in structural biology.